Orexo Interim Report Q3 2020
The new future starts to take shapeQ3 2020 highlights · Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US · Net earnings of SEK -84.9 m (111.7), net earnings of SEK -22.4 m excluding DTx launch. Net earnings also impacted by a material one-time tax adjustment of SEK -43.5 m. · EBITDA of SEK -12.2 m (114.1), EBITDA of SEK 50.3 m excluding DTx launch · US Pharma segment (ZUBSOLV® US) net revenues of SEK 143.8 m (182.7), EBIT of SEK 72.4 m (90.9) · DTx segment EBIT of SEK -62.5 m (-), including US launch of the scientifically proven digital